Medanta Stock Analysis: ₹1,480 Target as New Noida Hospital Powers Growth Engine

Medanta's parent company Global Health Limited is expanding its healthcare footprint across North India. With a new 226-bed hospital in Noida and ambitious plans to nearly double capacity, analysts see significant upside ahead.

The stock carries a BUY rating with a target price of ₹1,480, that's 17% upside from the current price of ₹1,263.

 Live stock call: View on MO Alpha Advice

The Investment Thesis in 60 Seconds

Medanta is entering an expansion upcycle. The newly launched Noida hospital will drag FY26 margins temporarily, but this is a short-term headwind before a multi-year growth runway kicks in.

Here's what makes this compelling:

1. Near-term pain: The Noida hospital will generate an operating loss of ₹1.3 billion in FY26. EBITDA margins will dip to 22.5% from 24.1% in FY25.

2. Medium-term gain: Noida expected to break even within 12-15 months. Profitability should scale up from Q4 FY27 onwards.

3. Long-term visibility: Capacity expanding from 3,042 beds (FY25) to 6,382 beds (beyond FY27). That's more than doubling the network.

4. Financial firepower: ₹7 billion surplus cash plus ₹32 billion expected operating cash flow over five years can fund the ₹41 billion capex program without stress.

Read more: Top Investment Mistakes to Avoid

Why Noida Changes the Game for Medanta

The new Noida hospital is strategically positioned to capture demand from an underserved 250 km radius covering Western UP, South Delhi, Uttarakhand, Haryana, and parts of Rajasthan.

The Supply-Demand Mismatch

Noida-Greater Noida currently has approximately 6,000 superspecialty beds across all private providers. That sounds like a lot until you consider the catchment area includes major population centers like Meerut, Bulandshahr, Aligarh, Agra, and Mathura, all with limited access to quaternary care.

Patients from these areas currently travel to central Delhi or Gurugram for complex procedures. Medanta Noida offers a closer, equally capable alternative.

What Medanta Noida Brings

The 226-bed facility (scalable to 550 beds) opened in September 2025 with:

• 80 ICU beds
• 20+ specialties operational
• 150+ doctors onboarded, including 30+ senior clinicians
• Advanced technology: Da Vinci Xi robotic surgery system, AI-driven cath lab, 3T MRI, dual-source CT, PET scanner

Initial traction has been encouraging, ₹39 million revenue in the first month despite being at early-stage occupancy. Insurance empanelment is progressing and should unlock meaningful volume growth in coming months.

Hospital-by-Hospital Breakdown

Medanta operates three categories of hospitals, each at different maturity stages:

Mature Hospitals (Gurugram, Indore, Ranchi)

These are the profit engines generating consistent cash flows.

The temporary occupancy dip in FY26 reflects the 140-bed addition at Ranchi. As these beds fill up, occupancy and margins normalize.

Developing Hospitals (Lucknow, Patna)

These are the growth drivers with operating leverage still playing out.

Lucknow and Patna deliver 30%+ EBITDA margins, higher than mature hospitals. This reflects the operating leverage from scaling up a well-established patient franchise.

Upcoming Hospital (Noida)

This is the near-term drag but long-term opportunity.

The path to profitability is clear: occupancy ramps from 7% to 40% by FY28, and EBITDA turns positive.

The Expansion Pipeline: 3,042 to 6,382 Beds

Medanta has laid out an aggressive but credible expansion roadmap.

Current capacity (FY25): 3,042 beds

FY26 additions: 667 beds

• Patna: 157 beds (57 added in H1, 100 in H2)
• Ranchi: 110 beds
• Noida: 226 beds
• Lucknow: 100 beds (H2)

FY27 additions: 373 beds

• Lucknow: 100 beds
• Patna: 23 beds
• Noida: 250 beds

Total by FY27: 4,082 beds

Beyond FY27: 2,300 additional beds planned

• Mumbai: 750-bed super-specialty hospital
• Delhi Pitampura: 750 beds
• Delhi South: 400 beds
• Guwahati: 400-bed super-specialty facility for Northeast India

Ultimate capacity: 6,382 beds

Financial Outlook: FY26-28 Projections

The numbers tell a story of temporary margin compression followed by acceleration.

Consolidated Financials

Margin Recovery Path

FY26 sees margin compression to 22.5% due to Noida losses. But watch the recovery:

• FY27: 25.7% (up 320 bps)
• FY28: 26.4% (up 70 bps)

By FY28, consolidated EBITDA margins should exceed the FY25 level of 24.1%.

Return Ratios

RoE expands 280 basis points from FY25 to FY28 as profitability scales without proportionate equity dilution.

Capital Allocation: Can Medanta Fund This Growth?

The ₹41 billion capex plan over five years is substantial. Here's how it gets funded:

Sources of funds:

• Surplus cash on books: ₹7 billion
• Expected operating cash flow (5 years): ~₹32 billion
• Total available: ₹39-40 billion

Uses of funds:

• Maintenance capex (3 years): ₹4.5 billion
• Growth projects: ₹36.7 billion
• Total requirement: ₹41 billion

The math is tight but workable. H1 FY26 operating cash flow of ₹3.2 billion annualized over five years gets to ₹32 billion. Combined with existing cash, this covers the capex program without significant debt addition.

Major project allocations:

• Mumbai hospital: ₹13.8 billion
• Pitampura (Delhi): ₹5.8 billion
• Guwahati: ₹5 billion

These three projects account for 72% of growth capex. All are scheduled to become operational from FY27.

Valuation: What Supports ₹1,480?

The target price of ₹1,480 is based on 30x 12-month forward EV/EBITDA multiple.

Current Valuation Metrics

Peer Comparison

Medanta trades at a discount to Max Healthcare and Apollo despite comparable growth. The Noida drag may be weighing on near-term sentiment, creating an entry opportunity.

Read more: How to Calculate the Valuation of a Company

Key Risks to Monitor

1. Execution risk on new hospitals: Mumbai, Pitampura, South Delhi, and Guwahati are all greenfield projects. Delays or cost overruns could impact returns.
    
2. Noida ramp-up slower than expected: If occupancy doesn't reach 40% by FY28, the profitability trajectory shifts out.
    
3. Doctor attrition: Healthcare delivery depends on clinical talent. While management noted minimal attrition during Noida ramp-up, this remains an ongoing risk.
    
4. Insurance empanelment delays: Volume growth at Noida depends on completing insurance tie-ups. Slower empanelment means slower occupancy ramp.
    
5. Competition in NCR: The Delhi-NCR market has multiple established players. Patient acquisition costs could be higher than modeled.
    
6. Regulatory changes: Healthcare pricing and insurance regulations evolve. Any adverse changes could impact realizations.

Recent Quarterly Performance: Q2 FY26

The most recent quarter shows the Noida impact beginning to flow through:

Revenue growth of 15% YoY is healthy. The margin compression reflects Noida losses flowing through consolidated numbers. This is expected and already factored into estimates.

Read more: How to Analyse Quarterly Results Using 8 Key Financial Ratios 

Who Should Consider This Stock?

Suitable for:

• Investors with 2-3 year horizon who can look through near-term margin pressure
• Those seeking healthcare sector exposure in a quality franchise
• Portfolios underweight on defensives with growth visibility
• Investors comfortable with premium valuations for premium businesses

Less suitable for:

• Income-focused investors (dividend yield at 0.3-0.4%)
• Those seeking immediate earnings growth (FY26 EPS growth constrained by Noida)
• Valuation-sensitive investors uncomfortable with 40x+ P/E
• Short-term traders looking for momentum

Frequently Asked Questions

1. What is Global Health (Medanta) target price?

The target price is ₹1,480, representing 17% upside from the current price of ₹1,263. This is based on 30x 12-month forward EV/EBITDA multiple, supported by 22% EPS CAGR through FY28 and a clear expansion roadmap.

2. Is Medanta stock a good buy now?

The stock carries a BUY recommendation. While FY26 margins will be temporarily depressed due to Noida hospital losses, this is a transient impact. The new hospital is expected to break even within 12-15 months, after which consolidated earnings should accelerate.

3. When will Medanta Noida hospital become profitable?

EBITDA breakeven is expected within 12-15 months (around mid-FY27). By FY28, the Noida hospital is projected to achieve 17.4% EBITDA margin at 40% occupancy, contributing ₹518 million to consolidated EBITDA.

4. How many beds will Medanta have?

Current capacity stands at 3,042 beds (FY25). This will expand to 4,082 beds by FY27 and ultimately to 6,382 beds beyond FY27 with new hospitals in Mumbai, Delhi (Pitampura and South Delhi), and Guwahati.

5. What is Medanta's revenue growth outlook?

Revenue is projected to grow at 13% CAGR from FY25 to FY28, reaching ₹53.2 billion. The developing hospitals (Lucknow, Patna) are expected to deliver 19% sales CAGR, while the new Noida facility adds incremental growth from a low base.

6. How does Medanta compare to Apollo and Max Healthcare?

Medanta trades at 43x FY27E P/E versus 48x for Apollo and 50x for Max Healthcare. PAT CAGR is comparable at 25% versus 24% for Apollo and 32% for Max. The valuation discount may reflect near-term Noida drag, presenting a potential entry point.

The Bottom Line for Medanta

Global Health (Medanta) is in expansion mode with a clear path from temporary margin compression to accelerating earnings. The new Noida hospital creates short-term noise but positions the company for multi-year growth.

Key numbers to remember: 17% upside to target, 22% EPS CAGR through FY28, capacity doubling to 6,382 beds, and breakeven at Noida within 12-15 months.

For investors with a 2-3 year view who can tolerate near-term margin pressure, this represents an opportunity to buy a premium healthcare franchise at a relative discount to peers.